Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016

Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016
Published Jun 28, 2016
56 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016, provides in depth analysis on Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted pipeline therapeutics.

The report provides comprehensive information on the Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large)
- The report reviews Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule ty

  
Source:
Document ID
GMDHC0141TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Overview71
Therapeutics Development83
  Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Products under Development by Stage of Development81
  Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Products under Development by Therapy Area91
  Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Products under Development by Indication101
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Products under Development by Companies132
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Products under Development by Universities/Institutes152
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Therapeutics Assessment175
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration191
  Assessment by Molecule Type202
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Companies Involved in Therapeutics Development223
  AbbVie Inc.221
  Princeton University231
  Takeda Pharmaceutical Company Limited241
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Drug Profiles2513
  ABT-737 Drug Profile251
  AT-101 Drug Profile264
  navitoclax dihydrochloride Drug Profile302
  rottlerin Drug Profile321
  Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology Drug Profile331
  Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology Drug Profile341
  Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology Drug Profile351
  Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology Drug Profile361
  WEHI-539 Drug Profile371
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Dormant Projects384
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Discontinued Products421
Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) Featured News &Press Releases4312
  Apr 22, 2013: Walter And Eliza Hall Institute Scientists And Their Collaborators Develop New Potential Anti-cancer Compound WEHI-539431
  Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting431
  Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting442
  Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting461
  May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting471
  May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting471
  Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer471
  Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer481
  Jan 26, 2007: Abbott And Genentech Announce Global, Integrated Research, Development And Commercialization Collaboration In Oncology491
  Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia501
  Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting511
  Dec 12, 2005: Ascenta AT-101 Data Presented At The American Society Of Hematology 47th Annual Meeting And Exposition In Atlanta, Georgia521
  Dec 12, 2005: Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia531
  Nov 18, 2005: Ascenta AT-101 Clinical Trial Data Presented At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer541
  Nov 10, 2005: Phase II Program Of Ascenta's Lead Product, AT-101, A Pan-inhibitor Of The Bcl-2 Protein Family, Begins541
Appendix552
  Methodology551
  Coverage551
  Secondary Research551
  Primary Research551
  Expert Panel Validation551
  Contact Us551
  Disclaimer561

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bcl-2-Like-Protein-1-Bcl-xl-or-Bcl2-L-1-or-Apoptosis-Regulator-Bcl-X-or-Protein-Phosphatase-1-Regulatory-Subunit-52-or-B-cell-Lymphoma-Extra-Large-Pipeline-Review-H1-2016-2088-16043>
  
APA:
Global Markets Direct - Market Research. (2016). Bcl-2-Like Protein 1 (Bcl-xl or Bcl2-L-1 or Apoptosis Regulator Bcl-X or Protein Phosphatase 1 Regulatory Subunit 52 or B-cell Lymphoma Extra Large) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bcl-2-Like-Protein-1-Bcl-xl-or-Bcl2-L-1-or-Apoptosis-Regulator-Bcl-X-or-Protein-Phosphatase-1-Regulatory-Subunit-52-or-B-cell-Lymphoma-Extra-Large-Pipeline-Review-H1-2016-2088-16043>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.